Literature DB >> 16211224

Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.

Stephan E Baldus1, Jens R Wienand, Jan P Werner, Stephanie Landsberg, Uta Drebber, Franz-Georg Hanisch, Hans P Dienes.   

Abstract

MUC1 represents a promising marker in breast cancer. However, due to the structural complexity of the MUC1 glycoprotein, multiple epitopes can be detected by monoclonal antibodies. This fact may be responsible for the contradictory results of previous investigations regarding the clinical and prognostic relevance of MUC1 expression in breast cancer. Therefore, we tried to evaluate the role of different glycosylated and non-glycoslyated MUC1 epitopes as well as other mucin-associated peptides (MUC2) and carbohydrates (Thomsen-Friedenreich antigen, sialyl-Lewisa, sialyl-Lewisx) as predictors of the clinical course and prognosis in mammary carcinomas. An immunohistochemical study applying numerous monoclonal antibodies (mabs) was performed to characterize the expression of a selected panel of MUC1 epitopes, and of MUC2, Thomsen-Friedenreich antigen, sialyl-Lewisa, and sialyl-Lewisx in a series of 140 patients with breast cancer. The results were correlated with clinicopathological variables as well as overall survival. Generally, more than 90% of the mammary cancers, were strongly stained with the MUC1-specific mabs. Especially ductal and lobular carcinomas were strongly MUC1- and sialyl Lewisa-positive, whereas MUC2 binding was significantly elevated in mucinous neoplasms. Associations between the immunoreactivity of any mab under study and tumor progression as reflected by pTNM staging could not be observed. However, expression of the sialylated MUC1 epitope detected by mab MY1.E12 was revealed as a favourable independent prognostic factor. These results confirm that MUC1 is generally strongly expressed in mammary carcinomas. As an exception, mucinous carcinomas are significantly less MUC1 reactive, but strongly express MUC2. Our data suggest that only the presence of a sialylated short-chain MUC1 glycoform is associated with a better prognosis, whereas the other molecules under study are not correlated with the course of disease and survival probability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211224

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Alterations in the serum glycome due to metastatic prostate cancer.

Authors:  Zuzana Kyselova; Yehia Mechref; Mohammad M Al Bataineh; Lacey E Dobrolecki; Robert J Hickey; Jake Vinson; Christopher J Sweeney; Milos V Novotny
Journal:  J Proteome Res       Date:  2007-04-14       Impact factor: 4.466

2.  Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.

Authors:  Yehia Mechref; Ahmed Hussein; Slavka Bekesova; Vitara Pungpapong; Min Zhang; Lacey E Dobrolecki; Robert J Hickey; Zane T Hammoud; Milos V Novotny
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

3.  Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.

Authors:  Qicheng Zhao; Xiuli Guo; Gerard B Nash; Philip C Stone; John Hilkens; Jonathan M Rhodes; Lu-Gang Yu
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

4.  Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Imelda S Quinlin; Khaliquzzaman A Samad; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Clin Immunol       Date:  2009-09-16       Impact factor: 3.969

Review 5.  The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.

Authors:  Lu-Gang Yu
Journal:  Glycoconj J       Date:  2007-04-25       Impact factor: 2.916

6.  Investigations with O-linked protein glycosylations by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Taufika Islam Williams; Diana A Saggese; Kristina L Toups; Jennifer L Frahm; Hyun Joo An; Bensheng Li; Carlito B Lebrilla; David C Muddiman
Journal:  J Mass Spectrom       Date:  2008-09       Impact factor: 1.982

7.  MUC1 drives c-Met-dependent migration and scattering.

Authors:  Teresa M Horm; Benjamin G Bitler; Derrick M Broka; Jeanne M Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

8.  Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Authors:  Mark D Pegram; Virginia F Borges; Nuhad Ibrahim; Jyotsna Fuloria; Charles Shapiro; Susan Perez; Karen Wang; Franziska Schaedli Stark; Nigel Courtenay Luck
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

Review 9.  Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.

Authors:  Oleg Kurtenkov
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.